Cargando…

Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy

BACKGROUND: The IgA nephropathy (IgAN) Study Group in Japan conducted a multicenter, randomized, controlled trial of tonsillectomy with steroid pulse therapy (TSP) versus steroid pulse monotherapy in patients with IgAN (UMIN Clinical Trial Registry Number; C000000384). The effects of therapies in re...

Descripción completa

Detalles Bibliográficos
Autores principales: Katafuchi, Ritsuko, Kawamura, Tetsuya, Joh, Kensuke, Hashiguchi, Akinori, Hisano, Satoshi, Shimizu, Akira, Miyazaki, Yoichi, Nagata, Masaharu, Matsuo, Seiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819588/
https://www.ncbi.nlm.nih.gov/pubmed/26349433
http://dx.doi.org/10.1007/s10157-015-1159-2
_version_ 1782425234900516864
author Katafuchi, Ritsuko
Kawamura, Tetsuya
Joh, Kensuke
Hashiguchi, Akinori
Hisano, Satoshi
Shimizu, Akira
Miyazaki, Yoichi
Nagata, Masaharu
Matsuo, Seiichi
author_facet Katafuchi, Ritsuko
Kawamura, Tetsuya
Joh, Kensuke
Hashiguchi, Akinori
Hisano, Satoshi
Shimizu, Akira
Miyazaki, Yoichi
Nagata, Masaharu
Matsuo, Seiichi
author_sort Katafuchi, Ritsuko
collection PubMed
description BACKGROUND: The IgA nephropathy (IgAN) Study Group in Japan conducted a multicenter, randomized, controlled trial of tonsillectomy with steroid pulse therapy (TSP) versus steroid pulse monotherapy in patients with IgAN (UMIN Clinical Trial Registry Number; C000000384). The effects of therapies in relation to pathological severity were analyzed in this study. METHODS: The patients with IgAN, urinary protein 1.0–3.5 g/day, serum creatinine of 1.5 mg/dl or less were randomly assigned to receiving TSP (Group A) or steroid pulses alone (Group B). The primary endpoint was the disappearance of proteinuria and/or hematuria. Twenty-six biopsies in Group A and 33 in Group B were available. The histological grades (HG) according to the percentage of glomeruli with crescent or sclerosis and the Oxford classification were analyzed. RESULTS: The patients in Group A had a 4.32- to 12.1-fold greater benefit of disappearance of proteinuria and 3.61- to 8.17-fold greater benefit of clinical remission (disappearance of proteinuria and hematuria) than those in Group B in patients with HG2–3, acute lesions (cellular or fibrocellular crescent) affecting more than 5 % of glomeruli, chronic lesions (fibrous crescents or sclerosis) affecting more than 20 % and S1. In contrast, odds ratios for disappearance of proteinuria or clinical remission in Group A to Group B were not significant in patients with HG 1, acute lesion in 5 % or less of glomeruli, chronic lesion in 20 % or less and S0. The disappearance of hematuria showed no relation to pathological severity. CONCLUSION: TSP might be better employed according to the pathological severity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10157-015-1159-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4819588
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-48195882016-04-10 Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy Katafuchi, Ritsuko Kawamura, Tetsuya Joh, Kensuke Hashiguchi, Akinori Hisano, Satoshi Shimizu, Akira Miyazaki, Yoichi Nagata, Masaharu Matsuo, Seiichi Clin Exp Nephrol Original Article BACKGROUND: The IgA nephropathy (IgAN) Study Group in Japan conducted a multicenter, randomized, controlled trial of tonsillectomy with steroid pulse therapy (TSP) versus steroid pulse monotherapy in patients with IgAN (UMIN Clinical Trial Registry Number; C000000384). The effects of therapies in relation to pathological severity were analyzed in this study. METHODS: The patients with IgAN, urinary protein 1.0–3.5 g/day, serum creatinine of 1.5 mg/dl or less were randomly assigned to receiving TSP (Group A) or steroid pulses alone (Group B). The primary endpoint was the disappearance of proteinuria and/or hematuria. Twenty-six biopsies in Group A and 33 in Group B were available. The histological grades (HG) according to the percentage of glomeruli with crescent or sclerosis and the Oxford classification were analyzed. RESULTS: The patients in Group A had a 4.32- to 12.1-fold greater benefit of disappearance of proteinuria and 3.61- to 8.17-fold greater benefit of clinical remission (disappearance of proteinuria and hematuria) than those in Group B in patients with HG2–3, acute lesions (cellular or fibrocellular crescent) affecting more than 5 % of glomeruli, chronic lesions (fibrous crescents or sclerosis) affecting more than 20 % and S1. In contrast, odds ratios for disappearance of proteinuria or clinical remission in Group A to Group B were not significant in patients with HG 1, acute lesion in 5 % or less of glomeruli, chronic lesion in 20 % or less and S0. The disappearance of hematuria showed no relation to pathological severity. CONCLUSION: TSP might be better employed according to the pathological severity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10157-015-1159-2) contains supplementary material, which is available to authorized users. Springer Japan 2015-09-09 2016 /pmc/articles/PMC4819588/ /pubmed/26349433 http://dx.doi.org/10.1007/s10157-015-1159-2 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Katafuchi, Ritsuko
Kawamura, Tetsuya
Joh, Kensuke
Hashiguchi, Akinori
Hisano, Satoshi
Shimizu, Akira
Miyazaki, Yoichi
Nagata, Masaharu
Matsuo, Seiichi
Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy
title Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy
title_full Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy
title_fullStr Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy
title_full_unstemmed Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy
title_short Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy
title_sort pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin a nephropathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819588/
https://www.ncbi.nlm.nih.gov/pubmed/26349433
http://dx.doi.org/10.1007/s10157-015-1159-2
work_keys_str_mv AT katafuchiritsuko pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy
AT kawamuratetsuya pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy
AT johkensuke pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy
AT hashiguchiakinori pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy
AT hisanosatoshi pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy
AT shimizuakira pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy
AT miyazakiyoichi pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy
AT nagatamasaharu pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy
AT matsuoseiichi pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy
AT pathologicalsubanalysisofamulticenterrandomizedcontrolledtrialoftonsillectomycombinedwithsteroidpulsetherapyversussteroidpulsemonotherapyinpatientswithimmunoglobulinanephropathy